ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Aprovel® 150/- 300:Sanofi-Aventis (Suisse) SA
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
C09CA04 - IrbesartanATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C09 - Agents Acting on The Renin-Angiotensin System
 

The DDDs are based on the treatment of mild-moderate hypertension.
See comments to C02L concerning the principles for assignment of DDDs for combined preparations.

C09C - Angiotensin Ii Receptor Blockers (Arbs), plain
 
C09CA - Angiotensin Ii Receptor Blockers (Arbs), plain
 
C09CA04 - Irbesartan
DoseRoute of administrationNote
 O 
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home